Diabetes

  • Diabetes has become widespread and is now becoming more recognized as a public health concern in Kuwaiti community as Kuwait is one of the top five countries in the world in the incidence of Diabetes in the adult population.
  • The number of people in Kuwait who have Diabetes has doubled in the last decade and it’s expected that the incidence of Diabetes will reach over 35% in 2025.
  • The aim is to deliver a complete solution for diabetic patients through providing leading diabetic medical products and patient education for greater disease awareness.
  • Initiated and participated in many diabetes-related campaigns, in cooperation with our principals, promoting Eli Lilly (Insulin), Abbott Diabetes Care (Glucose and Ketone monitoring system), Becton Dickinson (Insulin delivery system).

Abbott Diabetes Care

As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our customers. Consistent and accurate glucose monitoring is the foundation of any diabetes management plan so we’re committed to continuous improvement in the way patients and professionals measure, track and analyze glucose levels.

freestyle1

The FreeStyle Libre flash glucose monitoring system is designed to liberate patients from the hassles of glucose monitoring.

Becton Dickinson​ is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

For centuries, a diagnosis of diabetes was practically a death sentence; there were simply no effective treatments for the disease. But in 1923, everything changed: A ground-breaking collaboration between Lilly scientists and University of Toronto researchers led to the discovery and development of the world’s first commercially available insulin. In the nearly 100 years since, Lilly has continued our commitment to provide ever-better options for those living with diabetes, including treatments, resources and support programs to help along every step of their journey.

  • Basaglar® (insulin glargine injection)
  • Humalog® Junior KwikPen® (insulin lispro injection 100 units/mL)
  • Humalog® Mix50/50™ (50% insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin])
  • Humalog® Mix75/25™ (75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin])
  • Humalog® U100 (insulin lispro injection)
  • Humalog® U200 (insulin lispro injection)
  • Trulicity® (dulaglutide)